Cytokines released by granulocytes and mononuclear cells stimulate amnion cell prostaglandin E2 production.
Preterm labor is associated with histologic chorioamnionitis and intraamniotic infection. Chorioamnionitis is characterized by infiltration of the fetal membranes by granulocytes. In intraamniotic infection, white cells accumulate in amniotic fluid. Granulocytes and mononuclear cells have been shown to release products that stimulate prostaglandin E2 (PGE2) production by amnion cells. The aim of the present study was to identify some of these products. Cell-free supernatant obtained from formylmethionyl-leucyl-phenylalanine (FMLP)-activated granulocytes was subjected to size exclusion chromatography. The fractions obtained were analyzed for their stimulatory effect on PGE2 production by human amnion cells in culture. Two peaks of PGE2-stimulatory activity were found. The activity present in one of these was synergistic with interleukin-1 beta (IL-1 beta) in stimulating amnion cell PGE2 production and was found to contain mainly transforming growth factor-alpha (TGF-alpha) immunoreactivity. This cytokine originated at least in part from eosinophils. The PGE2-stimulatory activity present in the other peak contained IL-1 beta, epidermal growth factor (EGF), and tumor necrosis factor-alpha (TNF-alpha). The release of IL-beta, TNF-alpha, TGF-alpha, and EGF by granulocytes differed from that of mononuclear cells. We have previously shown that TGF-alpha and EGF are synergistic with IL-1 and TNF-alpha in enhancing amnion cell PGE2 production. The different pattern of prostaglandin-stimulatory cytokines released from different types of white cells suggest that the cells may potentiate each others' effects.
Bry
K
K
Department of Pediatrics, University of California, Irvine 92717.
Hallman
M
M
Lappalainen
U
U
D000650:Amnion / Q000378:metabolism*; D002850:Chromatography, Gel; D016207:Cytokines / Q000302:isolation & purification / Q000378:metabolism* / Q000494:pharmacology; D015232:Dinoprostone / Q000096:biosynthesis*; D004357:Drug Synergism; D004815:Epidermal Growth Factor / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006098:Granulocytes / Q000378:metabolism*; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D016211:Transforming Growth Factor alpha / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000494:pharmacology
D016207:Cytokines; D007375:Interleukin-1; D016211:Transforming Growth Factor alpha; D014409:Tumor Necrosis Factor-alpha; D009240:N-Formylmethionine Leucyl-Phenylalanine; D004815:Epidermal Growth Factor; D015232:Dinoprostone